secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0000875320-25-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex 2024 product revenue $11.02B (+12% YoY); GAAP loss $536M from IPR&D; FY2025 guidance $11.75-12.0B
--------------------------------------------------------------------------------

- Q4 product revenue $2.91B (+16% YoY); full-year product revenue $11.02B (+12%) driven by TRIKAFTA/KAFTRIO.
- GAAP net loss $536M for 2024 due to $4.4B AIPR&D from Alpine Immune Sciences acquisition; non-GAAP net income $111M.
- FY2025 total revenue guidance $11.75-12.0B; combined non-GAAP R&D, AIPR&D, SG&A expenses guided at $4.9-5.0B.
- COO Stuart Arbuckle retiring July 1, 2025; CFO Charlie Wagner to add COO role, Duncan McKechnie to become CCO.
- JOURNAVX approved Jan 30, 2025 for moderate-to-severe acute pain; ALYFTREK approved Dec 20, 2024 for CF ages 6+.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/0000875320-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/vrtx-20250204.htm
  HTML page:      https://secwatch.observer/filing/0000875320-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer